The idiopathic intracranial hypertension treatment trial clinical profile at baseline

Michael Wall, Mark J. Kupersmith, Karl D. Kieburtz, James J. Corbett, Steven E. Feldon, Deborah I. Friedman, David M. Katz, John L. Keltner, Eleanor B. Schron, Michael P. McDermott

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

IMPORTANCE To our knowledge, there are no large prospective cohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the disease. OBJECTIVE: To report the baseline clinical and laboratory features of patients enrolled in the Idiopathic Intracranial Hypertension Treatment Trial. DESIGN, SETTING, AND PARTICIPANTS: We collected data at baseline from questionnaires, examinations, automated perimetry, and fundus photography grading. Patients (n = 165) were enrolled from March 17, 2010, to November 27, 2012, at 38 academic and private practice sites in North America. All participants met the modified Dandy criteria for IIH and had a perimetric mean deviation between -2 dB and -7 dB. All but 4 participants were women. MAIN OUTCOMES AND MEASURES: Baseline and laboratory characteristics. RESULTS: The mean (SD) age of our patients was 29.0 (7.4) years and 4 (2.4%) were men. The average (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 39.9 (8.3). Headache was the most common symptom (84%). Transient visual obscurations occurred in 68%of patients, back pain in 53%, and pulse synchronous tinnitus in 52%. Only 32%reported visual loss. The average (SD) perimetric mean deviation in the worst eye was -3.5 (1.1) dB, (range, -2.0 to -6.4 dB) and in the best eye was -2.3 (1.1) dB (range, -5.2 to 0.8 dB). A partial arcuate visual field defect with an enlarged blind spot was the most common perimetric finding. Visual acuity was 85 letters or better (20/20) in 71%of the worst eyes and 77%of the best eyes. Quality of life measures, including the National Eye Institute Visual Function Questionnaire-25 and the Short Form-36 physical and mental health summary scales, were lower compared with population norms. CONCLUSIONS AND RELEVANCE: The Idiopathic Intracranial Hypertension Treatment Trial represents the largest prospectively analyzed cohort of untreated patients with IIH. Our data show that IIH is almost exclusively a disease of obese young women. Patients with IIH with mild visual loss have typical symptoms, may have mild acuity loss, and have visual field defects, with predominantly arcuate loss and enlarged blind spots that require formal perimetry for detection. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01003639.

Original languageEnglish (US)
Pages (from-to)693-701
Number of pages9
JournalJAMA Neurology
Volume71
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Pseudotumor Cerebri
Clinical Trials
Visual Field Tests
Optic Disk
Visual Fields
Therapeutics
National Eye Institute (U.S.)
Tinnitus
Photography
Private Practice
Back Pain
North America
Hypertension
Visual Acuity
Headache
Mental Health
Body Mass Index
Quality of Life
Weights and Measures

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Wall, M., Kupersmith, M. J., Kieburtz, K. D., Corbett, J. J., Feldon, S. E., Friedman, D. I., ... McDermott, M. P. (2014). The idiopathic intracranial hypertension treatment trial clinical profile at baseline. JAMA Neurology, 71(6), 693-701. https://doi.org/10.1001/jamaneurol.2014.133

The idiopathic intracranial hypertension treatment trial clinical profile at baseline. / Wall, Michael; Kupersmith, Mark J.; Kieburtz, Karl D.; Corbett, James J.; Feldon, Steven E.; Friedman, Deborah I.; Katz, David M.; Keltner, John L.; Schron, Eleanor B.; McDermott, Michael P.

In: JAMA Neurology, Vol. 71, No. 6, 2014, p. 693-701.

Research output: Contribution to journalArticle

Wall, M, Kupersmith, MJ, Kieburtz, KD, Corbett, JJ, Feldon, SE, Friedman, DI, Katz, DM, Keltner, JL, Schron, EB & McDermott, MP 2014, 'The idiopathic intracranial hypertension treatment trial clinical profile at baseline', JAMA Neurology, vol. 71, no. 6, pp. 693-701. https://doi.org/10.1001/jamaneurol.2014.133
Wall, Michael ; Kupersmith, Mark J. ; Kieburtz, Karl D. ; Corbett, James J. ; Feldon, Steven E. ; Friedman, Deborah I. ; Katz, David M. ; Keltner, John L. ; Schron, Eleanor B. ; McDermott, Michael P. / The idiopathic intracranial hypertension treatment trial clinical profile at baseline. In: JAMA Neurology. 2014 ; Vol. 71, No. 6. pp. 693-701.
@article{8b74755cc4e04954a8cbc3861b6da5aa,
title = "The idiopathic intracranial hypertension treatment trial clinical profile at baseline",
abstract = "IMPORTANCE To our knowledge, there are no large prospective cohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the disease. OBJECTIVE: To report the baseline clinical and laboratory features of patients enrolled in the Idiopathic Intracranial Hypertension Treatment Trial. DESIGN, SETTING, AND PARTICIPANTS: We collected data at baseline from questionnaires, examinations, automated perimetry, and fundus photography grading. Patients (n = 165) were enrolled from March 17, 2010, to November 27, 2012, at 38 academic and private practice sites in North America. All participants met the modified Dandy criteria for IIH and had a perimetric mean deviation between -2 dB and -7 dB. All but 4 participants were women. MAIN OUTCOMES AND MEASURES: Baseline and laboratory characteristics. RESULTS: The mean (SD) age of our patients was 29.0 (7.4) years and 4 (2.4{\%}) were men. The average (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 39.9 (8.3). Headache was the most common symptom (84{\%}). Transient visual obscurations occurred in 68{\%}of patients, back pain in 53{\%}, and pulse synchronous tinnitus in 52{\%}. Only 32{\%}reported visual loss. The average (SD) perimetric mean deviation in the worst eye was -3.5 (1.1) dB, (range, -2.0 to -6.4 dB) and in the best eye was -2.3 (1.1) dB (range, -5.2 to 0.8 dB). A partial arcuate visual field defect with an enlarged blind spot was the most common perimetric finding. Visual acuity was 85 letters or better (20/20) in 71{\%}of the worst eyes and 77{\%}of the best eyes. Quality of life measures, including the National Eye Institute Visual Function Questionnaire-25 and the Short Form-36 physical and mental health summary scales, were lower compared with population norms. CONCLUSIONS AND RELEVANCE: The Idiopathic Intracranial Hypertension Treatment Trial represents the largest prospectively analyzed cohort of untreated patients with IIH. Our data show that IIH is almost exclusively a disease of obese young women. Patients with IIH with mild visual loss have typical symptoms, may have mild acuity loss, and have visual field defects, with predominantly arcuate loss and enlarged blind spots that require formal perimetry for detection. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01003639.",
author = "Michael Wall and Kupersmith, {Mark J.} and Kieburtz, {Karl D.} and Corbett, {James J.} and Feldon, {Steven E.} and Friedman, {Deborah I.} and Katz, {David M.} and Keltner, {John L.} and Schron, {Eleanor B.} and McDermott, {Michael P.}",
year = "2014",
doi = "10.1001/jamaneurol.2014.133",
language = "English (US)",
volume = "71",
pages = "693--701",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - The idiopathic intracranial hypertension treatment trial clinical profile at baseline

AU - Wall, Michael

AU - Kupersmith, Mark J.

AU - Kieburtz, Karl D.

AU - Corbett, James J.

AU - Feldon, Steven E.

AU - Friedman, Deborah I.

AU - Katz, David M.

AU - Keltner, John L.

AU - Schron, Eleanor B.

AU - McDermott, Michael P.

PY - 2014

Y1 - 2014

N2 - IMPORTANCE To our knowledge, there are no large prospective cohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the disease. OBJECTIVE: To report the baseline clinical and laboratory features of patients enrolled in the Idiopathic Intracranial Hypertension Treatment Trial. DESIGN, SETTING, AND PARTICIPANTS: We collected data at baseline from questionnaires, examinations, automated perimetry, and fundus photography grading. Patients (n = 165) were enrolled from March 17, 2010, to November 27, 2012, at 38 academic and private practice sites in North America. All participants met the modified Dandy criteria for IIH and had a perimetric mean deviation between -2 dB and -7 dB. All but 4 participants were women. MAIN OUTCOMES AND MEASURES: Baseline and laboratory characteristics. RESULTS: The mean (SD) age of our patients was 29.0 (7.4) years and 4 (2.4%) were men. The average (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 39.9 (8.3). Headache was the most common symptom (84%). Transient visual obscurations occurred in 68%of patients, back pain in 53%, and pulse synchronous tinnitus in 52%. Only 32%reported visual loss. The average (SD) perimetric mean deviation in the worst eye was -3.5 (1.1) dB, (range, -2.0 to -6.4 dB) and in the best eye was -2.3 (1.1) dB (range, -5.2 to 0.8 dB). A partial arcuate visual field defect with an enlarged blind spot was the most common perimetric finding. Visual acuity was 85 letters or better (20/20) in 71%of the worst eyes and 77%of the best eyes. Quality of life measures, including the National Eye Institute Visual Function Questionnaire-25 and the Short Form-36 physical and mental health summary scales, were lower compared with population norms. CONCLUSIONS AND RELEVANCE: The Idiopathic Intracranial Hypertension Treatment Trial represents the largest prospectively analyzed cohort of untreated patients with IIH. Our data show that IIH is almost exclusively a disease of obese young women. Patients with IIH with mild visual loss have typical symptoms, may have mild acuity loss, and have visual field defects, with predominantly arcuate loss and enlarged blind spots that require formal perimetry for detection. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01003639.

AB - IMPORTANCE To our knowledge, there are no large prospective cohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the disease. OBJECTIVE: To report the baseline clinical and laboratory features of patients enrolled in the Idiopathic Intracranial Hypertension Treatment Trial. DESIGN, SETTING, AND PARTICIPANTS: We collected data at baseline from questionnaires, examinations, automated perimetry, and fundus photography grading. Patients (n = 165) were enrolled from March 17, 2010, to November 27, 2012, at 38 academic and private practice sites in North America. All participants met the modified Dandy criteria for IIH and had a perimetric mean deviation between -2 dB and -7 dB. All but 4 participants were women. MAIN OUTCOMES AND MEASURES: Baseline and laboratory characteristics. RESULTS: The mean (SD) age of our patients was 29.0 (7.4) years and 4 (2.4%) were men. The average (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 39.9 (8.3). Headache was the most common symptom (84%). Transient visual obscurations occurred in 68%of patients, back pain in 53%, and pulse synchronous tinnitus in 52%. Only 32%reported visual loss. The average (SD) perimetric mean deviation in the worst eye was -3.5 (1.1) dB, (range, -2.0 to -6.4 dB) and in the best eye was -2.3 (1.1) dB (range, -5.2 to 0.8 dB). A partial arcuate visual field defect with an enlarged blind spot was the most common perimetric finding. Visual acuity was 85 letters or better (20/20) in 71%of the worst eyes and 77%of the best eyes. Quality of life measures, including the National Eye Institute Visual Function Questionnaire-25 and the Short Form-36 physical and mental health summary scales, were lower compared with population norms. CONCLUSIONS AND RELEVANCE: The Idiopathic Intracranial Hypertension Treatment Trial represents the largest prospectively analyzed cohort of untreated patients with IIH. Our data show that IIH is almost exclusively a disease of obese young women. Patients with IIH with mild visual loss have typical symptoms, may have mild acuity loss, and have visual field defects, with predominantly arcuate loss and enlarged blind spots that require formal perimetry for detection. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01003639.

UR - http://www.scopus.com/inward/record.url?scp=84902200145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902200145&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2014.133

DO - 10.1001/jamaneurol.2014.133

M3 - Article

C2 - 24756302

AN - SCOPUS:84902200145

VL - 71

SP - 693

EP - 701

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 6

ER -